This animation is provided for general information only. It is not intended to provide clinical instructions for use (IFU). Always read and understand the IFU supplied with the device prior to use.

PRESS RELEASEs

Intact Vascular Adds Howard Rosen to its Executive Management Team as VP Marketing and Business Development

May 1, 2017 - WAYNE, Pa.--(BUSINESS WIRE)--Intact Vascular, Inc., a developer of medical devices for minimally invasive peripheral vascular procedures, today announced that Howard Rosen has joined its executive management team as Vice President of Marketing and Business Development.  In …

Intact Vascular Announces Completion of Enrollment in the Tack Optimized Balloon Angioplasty II (TOBA II) Clinical Trial

March 23, 2017 - WAYNE, Pa.--(BUSINESS WIRE)--Intact Vascular, Inc., a developer of medical devices for minimally invasive peripheral vascular procedures, today announced that its Tack Optimized …

Intact Vascular’s Tack Optimized Balloon Angioplasty II Below the Knee (TOBA II BTK) Clinical Trial Commences Enrollment with First Implant of the Tack Endovascular System®

February 13, 2017 - WAYNE, Pa.--(BUSINESS WIRE)--Intact Vascular, Inc., a developer of medical devices for minimally invasive peripheral vascular procedures, today announced that its Tack Optimized …

Intact Vascular’s Tack Endovascular System® Secures CE Mark for Repair of Dissections Following Angioplasty Below the Knee

January 17, 2017 - WAYNE, Pa.--(BUSINESS WIRE)--Intact Vascular, Inc., a developer of medical devices for minimally invasive peripheral vascular procedures, today announced that it has attained the CE (Conformité Européenne) Mark for the Tack Endovascular System to repair arterial dissections fo…

Intact Vascular Closes on Additional Series B Funding to Advance Development of the Tack Endovascular System® for Peripheral Artery Disease Treatment

 January 3, 2017 - WAYNE, Pa.--(BUSINESS WIRE)--Intact Vascular, Inc., a developer of medical devices for minimally invasive peripheral vascular procedures, today announced that current investors New Enterprise Associates, Quaker Partners and H.I.G. BioHealth Partners have exercised their r…

FDA Approves TOBA II BTK Pivotal IDE Clinical Study

October 31, 2016 - WAYNE, Pa.--(BUSINESS WIRE)--Intact Vascular, Inc., a developer of medical devices for minimally invasive peripheral vascular procedures, today announced that the U.S. Food and Drug Administration (FDA) granted staged approval for the Company’s Investigational Device Exe…